Drug maker Merck & Co., Inc. (
) on Monday received some continued bullish support from analysts
The firm maintained its "Buy" rating and $42 price target on
UBS, which suggests an 8% upside to the stock's Friday closing
price of $38.94.
A UBS analyst noted he is not concerned right now about
potential generic competition for the company's Nasonex drug. On
Friday, a New Jersey judge ruled that generic competitor Apotex
does not infringe on Merck's patent for mometasone furoate
Merck shares were mostly flat in late morning trading
The Bottom Line
Shares of Merck (
) have a 4.31% dividend yield, based on Friday's closing stock
price of $38.94. The stock has technical support in the $36 price
area. If the shares can firm up, we see overhead resistance around
the $39-$40 price levels.
Merck & Co., Inc. (
) is not recommended at this time, holding a Dividend.com DARS™
Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here
Created by Dividend.com